Valion Bio (VIBO) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
17 Aug, 2026Opening remarks and agenda
CEO welcomed shareholders, emphasized the importance of their participation, and outlined the meeting's focus on addressing stock price and NASDAQ compliance.
General Counsel called the meeting to order, introduced executive management and board members, and explained voting procedures.
Specific resolutions to be voted on
Proposal to grant the board authority to amend the certificate of incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-50 within 12 months.
Proposal to authorize the board to adjourn the meeting if necessary to solicit additional proxies.
Board and executive committee updates
Board members and executive management were introduced, including the CEO, CFO, Chair, and other directors.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Valion Bio
- Net loss widened on higher R&D and CDMO costs, with urgent need for new funding and Nasdaq compliance risks.VIBO
Q2 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.VIBOProxy filing
- Biopharma pivots to Entolimod, raising up to $13.7M via flexible share/warrant offering.VIBORegistration filing
- Shareholders will vote on a reverse stock split to maintain Nasdaq compliance and potential adjournment authority.VIBOProxy filing
- All proposals passed as the company advances its clinical-stage biopharma strategy.VIBOAGM 2026
- Q1 2026 saw higher expenses, net loss, and liquidity risks amid strategic transformation.VIBOQ1 2026
- Shareholders will vote on director election, equity plan, auditor, and major share issuance approvals.VIBOProxy filing
- Board recommends approval of director, equity plan, auditor, and major share issuance proposals.VIBOProxy filing
- Late-stage immune therapies advance toward approval, with Entolimod targeting ARS and neutropenia.VIBOEmerging Growth Conference 91